Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Henry

Showing results (1111-1120 of 1,277) with videos related to

Pageof 128
Sort By:
JAMA Network Open|November 16, 2023
Mortality in ST-Segment Elevation Myocardial Infarction With Nonobstructive Coronary Arteries and MimickersOdayme Quesada, Mehmet Yildiz, Timothy D Henry, et al.
Scientific Reports|March 8, 2018
Author Correction: Circulating Biomarkers to Identify Responders in Cardiac Cell therapyJesse V Jokerst, Nicholas Cauwenberghs, Tatiana Kuznetsova, et al.
American Heart Journal|May 28, 2013
A phase 3, randomized, double-blinded, active-controlled, unblinded standard of care study assessing the efficacy and safety of intramyocardial autologous CD34+ cell administration in patients with refractory angina: design of the RENEW studyThomas J Povsic, Candice Junge, Adel Nada, et al.
Basic Research in Cardiology|November 25, 2016
Identification of cardiovascular risk factors associated with bone marrow cell subsets in patients with STEMI: a biorepository evaluation from the CCTRN TIME and LateTIME clinical trialsAriadna Contreras, Aaron F Orozco, Micheline Resende, et al.
Circulation|March 19, 2003
The VIVA trial: Vascular endothelial growth factor in Ischemia for Vascular AngiogenesisTimothy D Henry, Brian H Annex, George R McKendall, et al.
American Heart Journal|December 6, 2011
Developing mechanistic insights into cardiovascular cell therapy: Cardiovascular Cell Therapy Research Network Biorepository Core Laboratory rationaleClaudia Zierold, Marjorie A Carlson, Udo C Obodo, et al.
Cell Reports|March 26, 2025
Antagonistic roles for MITF and TFE3 in melanoma plasticityJeremy Chang, Katelyn R Campbell-Hanson, Marion Vanneste, et al.
Scientific Reports|July 2, 2017
Circulating Biomarkers to Identify Responders in Cardiac Cell therapyJesse V Jokerst, Nicholas Cauwenberghs, Tatiana Kuznetsova, et al.
JACC. Cardiovascular Interventions|July 4, 2016
The Impact of Timing of Ischemic and Hemorrhagic Events on Mortality After Percutaneous Coronary Intervention: The ADAPT-DES StudySorin J Brener, Ajay J Kirtane, Thomas D Stuckey, et al.
European Heart Journal|January 10, 2018
Autologous CD34+ cell therapy improves exercise capacity, angina frequency and reduces mortality in no-option refractory angina: a patient-level pooled analysis of randomized double-blinded trialsTimothy D Henry, Douglas W Losordo, Jay H Traverse, et al.
Pageof 128

Showing results (1111-1120 of 1,277) with videos related to

Sort By:
Pageof 128
JAMA Network Open|November 16, 2023
Mortality in ST-Segment Elevation Myocardial Infarction With Nonobstructive Coronary Arteries and MimickersOdayme Quesada, Mehmet Yildiz, Timothy D Henry, et al.
Scientific Reports|March 8, 2018
Author Correction: Circulating Biomarkers to Identify Responders in Cardiac Cell therapyJesse V Jokerst, Nicholas Cauwenberghs, Tatiana Kuznetsova, et al.
American Heart Journal|May 28, 2013
A phase 3, randomized, double-blinded, active-controlled, unblinded standard of care study assessing the efficacy and safety of intramyocardial autologous CD34+ cell administration in patients with refractory angina: design of the RENEW studyThomas J Povsic, Candice Junge, Adel Nada, et al.
Basic Research in Cardiology|November 25, 2016
Identification of cardiovascular risk factors associated with bone marrow cell subsets in patients with STEMI: a biorepository evaluation from the CCTRN TIME and LateTIME clinical trialsAriadna Contreras, Aaron F Orozco, Micheline Resende, et al.
Circulation|March 19, 2003
The VIVA trial: Vascular endothelial growth factor in Ischemia for Vascular AngiogenesisTimothy D Henry, Brian H Annex, George R McKendall, et al.
American Heart Journal|December 6, 2011
Developing mechanistic insights into cardiovascular cell therapy: Cardiovascular Cell Therapy Research Network Biorepository Core Laboratory rationaleClaudia Zierold, Marjorie A Carlson, Udo C Obodo, et al.
Cell Reports|March 26, 2025
Antagonistic roles for MITF and TFE3 in melanoma plasticityJeremy Chang, Katelyn R Campbell-Hanson, Marion Vanneste, et al.
Scientific Reports|July 2, 2017
Circulating Biomarkers to Identify Responders in Cardiac Cell therapyJesse V Jokerst, Nicholas Cauwenberghs, Tatiana Kuznetsova, et al.
JACC. Cardiovascular Interventions|July 4, 2016
The Impact of Timing of Ischemic and Hemorrhagic Events on Mortality After Percutaneous Coronary Intervention: The ADAPT-DES StudySorin J Brener, Ajay J Kirtane, Thomas D Stuckey, et al.
European Heart Journal|January 10, 2018
Autologous CD34+ cell therapy improves exercise capacity, angina frequency and reduces mortality in no-option refractory angina: a patient-level pooled analysis of randomized double-blinded trialsTimothy D Henry, Douglas W Losordo, Jay H Traverse, et al.
Pageof 128